Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.
Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH. Marsh RA, et al. Among authors: kumar ar. Blood. 2013 Feb 7;121(6):877-83. doi: 10.1182/blood-2012-06-432500. Epub 2012 Nov 6. Blood. 2013. PMID: 23131490 Free PMC article.
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH. Marsh RA, et al. Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10. Biol Blood Marrow Transplant. 2013. PMID: 24035782 Free PMC article.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Marsh RA, et al. Among authors: kumar ar. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10. Biol Blood Marrow Transplant. 2015. PMID: 25865646 Free PMC article.
Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.
Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosée P, Weitzman S; Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society. Lehmberg K, et al. Haematologica. 2015 Aug;100(8):997-1004. doi: 10.3324/haematol.2015.123562. Haematologica. 2015. PMID: 26314082 Free PMC article.
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, Jordan MB, Mehta PA, Jodele S, Grimley MS, Kumar A, Myers KC, Marsh RA. Khandelwal P, et al. Biol Blood Marrow Transplant. 2016 Dec;22(12):2220-2225. doi: 10.1016/j.bbmt.2016.09.016. Epub 2016 Sep 21. Biol Blood Marrow Transplant. 2016. PMID: 27664325 Free PMC article.
316 results